1-O-(α-D-galactosyl)-N-hexacosanoylphytosphingosine

Names

[ Name ]:
1-O-(α-D-galactosyl)-N-hexacosanoylphytosphingosine

[Synonym ]:
Krn 7000
Galalpha-Cer(t18:0/26:0)
Hexacosanamide, N-[(1S,2S,3R)-1-[(α-D-galactopyranosyloxy)methyl]-2,3-dihydroxyheptadecyl]-
N-[(2S,3S,4R)-3,4-dihydroxy-1-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadecan-2-yl]hexacosanamide
AGL-582
1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine
N-[(2S,3S,4R)-1-(α-D-Galactopyranosyloxy)-3,4-dihydroxy-2-octadecanyl]hexacosanamide
1-O-(α-D-galactosyl)-N-hexacosanoylphytosphingosine

Biological Activity

[Description]:

α-Galactosylceramide (α-GalCer) is a synthetic glycolipid with antitumorial and immunostimulatory. α-Galactosylceramide is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide plus CD1d binds the NKT cell TCR (T cell antigen receptor)[1][2][3][4].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

[Target]

NKT cell[3]

[In Vitro]

Culture supernatants of activated Vα24+NKT-cell cultures stimulated with α-Galactosylceramide pulsed monocyte-derived dendritic cells (Mo-DCs) exhibits antiproliferative activities against melanoma cells. This effect is predominantly due to release of IFN-γ, and to a lesser extent IL-12. Other cytokines, including IL-4 and IL-10, are released but these cytokines have less antiproliferative effects. Vα24+NKT-cells stimulated by α-Galactosylceramide-pulsed Mo-DCs have anti-tumour activities against human melanoma through antiproliferative effects exerted by soluble mediators[3].

[In Vivo]

α-Galactosylceramide treatment can protect against spontaneous, carcinogen-, or oncogene-induced primary tumor formation in mice. Consistent with a prime role for IFN-γ in NKT cell-mediated tumor responses, a C-glycoside analog of α-Galactosylceramide that preferentially stimulated IFN-γ production is even more effective than α-Galactosylceramide at preventing metastases of the B16 melanoma[1]. Since α-Galactosylceramide shows a potent antitumor activity and stimulates the lymphocyte proliferation (LP) on allogeneic mixed lymphocyte reaction (MLR) in the mouse, α-Galactosylceramide is considered to be a nonspecific immunostimulating agent which is a biological response modifier[4].

[References]

[1]. Godfrey DI, et al. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest. 2004 Nov;114(10):1379-88.

[2]. Morita M, et al. Practical Total Synthesis of (2S,3S,4R)-1-O-(α-D-Galactopyranosyl)-N-hexacosanoyl-2-amino-1,3,4-octadecanetriol, the Antitumorial and Immunostimulatory α-Galactosylcer-amide, KRN7000. Biosci Biotechnol Biochem. 1996 Jan;60(2):288-92.

[3]. Kikuchi A, et al. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma. Br J Cancer. 2001 Sep 1;85(5):741-6.

[4]. Masahiro Morita, et al. Structure-Activity Relationship of .alpha.-Galactosylceramides against B16-Bearing Mice. J. Med. Chem. 1995, 38, 12, 2176-2187.

Chemical & Physical Properties

[ Density]:
1.0±0.1 g/cm3

[ Boiling Point ]:
939.8±65.0 °C at 760 mmHg

[ Melting Point ]:
190 °C

[ Molecular Formula ]:
C₅₀H₉₉NO₉

[ Molecular Weight ]:
858.322

[ Flash Point ]:
522.2±34.3 °C

[ Exact Mass ]:
857.731995

[ PSA ]:
168.94000

[ LogP ]:
15.96

[ Vapour Pressure ]:
0.0±0.6 mmHg at 25°C

[ Index of Refraction ]:
1.512

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.